查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1193141

芽生菌病市場：按配方、藥物類型、分銷渠道分類：2021-2031 年全球機會分析和行業預測

Blastomycosis Market By Formulation, By Drug Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 240 Pages | 商品交期: 2-3個工作天內

價格

芽生菌病是一種真菌感染，由寄生在木材和土壤中的皮芽生菌引起。

芽生菌孢子在吸入時通過空氣進入人體，主要影響肺部並引起肺炎。 真菌通過血液傳播到身體的其他部位。 芽生菌病的症狀通常與其他肺部感染的症狀相似，包括咳嗽、盜汗、肌肉和關節痛、體重減輕、胸痛和疲勞。

如果芽生菌病感染擴散到皮膚，則可以在輕度至中度病例中使用唑類、烯丙胺類、棘白菌素類和多烯類等治療劑。

推動芽生菌病市場增長的主要因素是：治療芽生菌病新藥的開發增加，肺炎、結核病和非感染性肺病等慢性病的患病率增加。這些包括真菌病的增加患者和唑類藥物在芽生菌病治療中的高流行率。 此外，傳染病發病率和流行率的增加以及免疫功能低下人群（易患傳染病的人）的增加正在推動市場的增長。

例如，根據美國疾病控制與預防中心的數據，2021 年美國將報告 7,860 例結核病 (TB) 病例（每 100,000 人中有 2.4 例）。 在美國，多達 1300 萬人患有 LTBI。 因此，芽生菌患者越來越多，治療芽​​生菌的需求也越來越大。 因此，這些因素推動了芽生菌藥物的生長。

例如，根據世界衛生組織 (WHO) 的數據，到 2021 年全球將有 3480 萬人感染艾滋病毒，65 萬人將死於與艾滋病毒相關的疾病。 據此，2021年將有150萬人感染HIV。 因此，這些HIV患者由於對HIV的免疫力較弱，易患芽生菌病。

然而，不利的報銷以及藥物和芽生菌藥物的高成本等因素預計會阻礙市場增長。 另一方面，新興國家未被滿足的醫療需求和新興國家有利的商機，未來有望為全球芽生菌治療藥物生產商帶來巨大商機。

此外，隨著免疫功能低下患者數量的增加，獲得性免疫缺陷綜合症 (AIDS) 的流行，增加了芽生菌病的易感性，推動了芽生菌病市場的增長，預計醫療保健業務將呈現增長。 此外，越來越多的安全有效的芽生菌病治療藥物的發現和開發，以及對使用唑類藥物治療芽生菌病的認識不斷提高，正在推動芽生菌病市場的增長。 因此，預計在預測期內將為主要參與者提供有利可圖的市場投資機會。

此外，研發投入激增，唑類臨床研究增加，發達國家資本收益顯著上升，各大企業採取的收購、合作、產品發佈等重大戰略激增市場對芽生菌的需求。

例如，2021 年 6 月，Celon Laboratories Pvt. Ltd. 宣佈推出用於治療真菌感染的兩性黴素 B 乳劑 "AMFIGHT" 。 這種基於乳液的製劑是脂質體兩性黴素 B 治療黑素菌病的極佳替代品。 自 2013 年以來，Theron 一直在生產脂質體兩性黴素 B，但缺乏來自德國的關鍵成分類脂，使其無法滿足市場需求。 為了避免這種採購瓶頸並增加這種藥物的產量，Theron 開發了一種替代乳劑配方。 AMFIGHT 的推出加強了公司的抗真菌產品組合。 此類產品的推出將推動芽生菌市場的增長。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • COVID-19 影響分析

第 4 章芽生菌病市場：按配方分類

  • 概覽
    • 市場規模和預測
  • 藥片
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 藥膏
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 粉末
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 液體
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 5 章芽生菌病市場：按藥物類型分類

  • 概覽
    • 市場規模和預測
  • 唑類
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 多烯
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 6 章芽生菌病市場：按分銷渠道

  • 概覽
    • 市場規模和預測
  • 醫院和配藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 在線藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 零售藥房
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 7 章芽生菌市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機遇
    • 北美市場規模和預測：按劑型分類
    • 北美市場規模和預測：按藥物類型
    • 北美市場規模和預測：按分銷渠道
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機遇
    • 歐洲市場規模和預測：按配方分類
    • 歐洲市場規模和預測：按藥物類型
    • 歐洲市場規模和預測：按分銷渠道
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲地區
  • 亞太地區
    • 主要趨勢和機遇
    • 亞太市場規模和預測：按配方分類
    • 亞太市場規模和預測：按藥物類型
    • 亞太市場規模和預測：按分銷渠道
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 中國
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機遇
    • LAMEA 市場規模和預測：按配方分類
    • LAMEA 市場規模和預測：按藥物類型
    • LAMEA 市場規模和預測：按分銷渠道
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 南非
      • 沙特阿拉伯
      • LAMEA 的其餘部分

第八章公司情況

  • 簡介
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第九章公司簡介

  • Pfizer Inc.
  • Sanofi
  • Merck and Company
  • GSK
  • johnson and johnson md&d
  • Abbott Laboratories
  • CELON LABORATORIES LIMITED
  • Sun Pharmaceuticals Ltd
  • Astellas Pharma Inc.
  • Cipla Ltd
Product Code: A15629

Blastomycosis is a type of fungal infection caused by the fungus Blastomyces dermatitidis, which grows in wood and soil. Spores of Blastomyces enter the body through air, when inhaled, thus it mainly affects the lung and causes pneumonia. Fungi are spread through the bloodstream to other parts of the body. The symptoms of blastomycosis are often similar to the symptoms of other lung infections and can include cough, night sweats, muscle aches or joint pain, weight loss, chest pain, and fatigue.

When blastomycosis infection is spread in the skin, treatments such as azole, allylamines, echinocandins, and polyenes can be given in mild to moderate cases of blastomycosis infection.

Major factors driving the growth of the blastomycosis market include a rise in the development of new medicine for the treatment of blastomycosis infection, an increase in the prevalence rate of chronic diseases such as pneumonia, tuberculosis, a non-infectious pulmonary disease that have led to increases in a number of blastomycosis patients, and high adoption of azoles for the treatment of blastomycosis. Further, growth in the incidence and prevalence rate of infectious diseases and the rise in the population of immunocompromised (prone to infectious diseases) individuals enhance the growth of this market.

For instance, according to the Centers for Disease Control and Prevention, 7,860 tuberculosis (TB) cases were reported in the U.S. in 2021 (a rate of 2.4 per 100,000 persons). In the U.S., up to 13 million people live with latent TB infection. This has led to an increase in the number of blastomycosis patients, which increases the demand for blastomycosis treatment. Hence, such factors drive the growth of blastomycosis treatment.

For instance, according to World Health Organization (WHO), 34.8 million people were living with HIV worldwide in 2021 and 650,000 people died of HIV-related illnesses worldwide in 2021. According to this 1.5 million people acquiring HIV in 2021. Hence, these HIV patients are more vulnerable to blastomycosis, owing to weak immunity to HIV.

However, unfavorable reimbursements as well as complications such as high costs of medicine and drugs for blastomycosis are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for blastomycosis medicine manufacturers worldwide in the future.

Furthermore, the healthcare business is projected to witness growth owing to a rise in immunocompromised patients, a rise in the prevalence of acquired immunodeficiency syndrome (AIDS), that are more vulnerable to blastomycosis, and a boost in the growth of the blastomycosis market. In addition, an increase in the discovery & development of safe and effective medicine for blastomycosis and a rise in awareness regarding the use of azoles for the treatment of blastomycosis drive the growth of the blastomycosis market. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

Moreover, a rise in R&D investments, an increase in azoles-assisted clinical research studies, a significant rise in the capital income in developed countries, and a surge in key strategies such as acquisition, collaboration, and product launch, adopted by key players strengthen the demand for blastomycosis in the market.

For instance, in June 2021, Celon Laboratories Pvt. Ltd. announced the launch of AMFIGHT, an amphotericin B emulsion, used in the treatment of fungal infection. The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. Though Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany - lipoids. To bypass the bottleneck caused by this sourcing obstacle and increase the production of this medication, Celon developed an alternative, an emulsion-based formulation. The launch of AMFIGHT will help the company to strengthen its anti-fungal product portfolio. This type of product launch boosts the growth of the blastomycosis market.

The blastomycosis market is segmented on the basis of formulation, drug type, distribution channel, and region. On the basis of formulation, the market is classified into tablets, ointment, powder, and liquid. On the basis of drug type, the market is classified into azoles, polyenes, and others. Depending on the distribution channel, it is fragmented into hospital & clinical pharmacy, online pharmacy, and retail pharmacy. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players profiled in the report are Abbott Laboratories, Astellas Pharma Inc., Celon Laboratories Pvt. Ltd., Cipla Ltd, GlaxoSmithKline plc, Johnson and Johnson, Merck KGaA, Pfizer Inc., Sanofi S.A., and Sun Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the blastomycosis market analysis from 2021 to 2031 to identify the prevailing blastomycosis market opportunities.

Market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.

An in-depth analysis of the blastomycosis market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes an analysis of the regional as well as global blastomycosis market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Azoles
  • Polyenes
  • Others

By Distribution Channel

  • Hospital and Clinical Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By Formulation

  • Tablets
  • Ointment
  • Powder
  • Liquid

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA
  • Key Market Players
    • Pfizer Inc.
    • Sanofi
    • Merck and Company
    • GSK
    • johnson and johnson md&d
    • Abbott Laboratories
    • CELON LABORATORIES LIMITED
    • Sun Pharmaceuticals Ltd
    • Astellas Pharma Inc.
    • Cipla Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: BLASTOMYCOSIS MARKET, BY FORMULATION

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Tablets
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Ointment
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
  • 4.4 Powder
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country
  • 4.5 Liquid
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market share analysis by country

CHAPTER 5: BLASTOMYCOSIS MARKET, BY DRUG TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Azoles
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Polyenes
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country
  • 5.4 Others
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market share analysis by country

CHAPTER 6: BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital and Clinical Pharmacy
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Online Pharmacy
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Retail Pharmacy
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: BLASTOMYCOSIS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Formulation
    • 7.2.3 North America Market size and forecast, by Drug Type
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Formulation
      • 7.2.5.1.3 Market size and forecast, by Drug Type
      • 7.2.5.1.4 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Formulation
      • 7.2.5.2.3 Market size and forecast, by Drug Type
      • 7.2.5.2.4 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Formulation
      • 7.2.5.3.3 Market size and forecast, by Drug Type
      • 7.2.5.3.4 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Formulation
    • 7.3.3 Europe Market size and forecast, by Drug Type
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Formulation
      • 7.3.5.1.3 Market size and forecast, by Drug Type
      • 7.3.5.1.4 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Formulation
      • 7.3.5.2.3 Market size and forecast, by Drug Type
      • 7.3.5.2.4 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Formulation
      • 7.3.5.3.3 Market size and forecast, by Drug Type
      • 7.3.5.3.4 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Formulation
      • 7.3.5.4.3 Market size and forecast, by Drug Type
      • 7.3.5.4.4 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Formulation
      • 7.3.5.5.3 Market size and forecast, by Drug Type
      • 7.3.5.5.4 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Formulation
      • 7.3.5.6.3 Market size and forecast, by Drug Type
      • 7.3.5.6.4 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Formulation
    • 7.4.3 Asia-Pacific Market size and forecast, by Drug Type
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 China
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Formulation
      • 7.4.5.1.3 Market size and forecast, by Drug Type
      • 7.4.5.1.4 Market size and forecast, by Distribution Channel
      • 7.4.5.2 India
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Formulation
      • 7.4.5.2.3 Market size and forecast, by Drug Type
      • 7.4.5.2.4 Market size and forecast, by Distribution Channel
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Formulation
      • 7.4.5.3.3 Market size and forecast, by Drug Type
      • 7.4.5.3.4 Market size and forecast, by Distribution Channel
      • 7.4.5.4 South Korea
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Formulation
      • 7.4.5.4.3 Market size and forecast, by Drug Type
      • 7.4.5.4.4 Market size and forecast, by Distribution Channel
      • 7.4.5.5 Rest of Asia-Pacific
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Formulation
      • 7.4.5.5.3 Market size and forecast, by Drug Type
      • 7.4.5.5.4 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Formulation
    • 7.5.3 LAMEA Market size and forecast, by Drug Type
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Formulation
      • 7.5.5.1.3 Market size and forecast, by Drug Type
      • 7.5.5.1.4 Market size and forecast, by Distribution Channel
      • 7.5.5.2 South Africa
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Formulation
      • 7.5.5.2.3 Market size and forecast, by Drug Type
      • 7.5.5.2.4 Market size and forecast, by Distribution Channel
      • 7.5.5.3 Saudi Arabia
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Formulation
      • 7.5.5.3.3 Market size and forecast, by Drug Type
      • 7.5.5.3.4 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Formulation
      • 7.5.5.4.3 Market size and forecast, by Drug Type
      • 7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Pfizer Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Sanofi
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Merck and Company
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 GSK
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 johnson and johnson md&d
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Abbott Laboratories
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 CELON LABORATORIES LIMITED
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Sun Pharmaceuticals Ltd
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Astellas Pharma Inc.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Cipla Ltd
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. BLASTOMYCOSIS MARKET FOR TABLETS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. BLASTOMYCOSIS MARKET FOR TABLETS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. BLASTOMYCOSIS MARKET FOR OINTMENT, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. BLASTOMYCOSIS MARKET FOR OINTMENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. BLASTOMYCOSIS MARKET FOR POWDER, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. BLASTOMYCOSIS MARKET FOR POWDER, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. BLASTOMYCOSIS MARKET FOR LIQUID, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. BLASTOMYCOSIS MARKET FOR LIQUID, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. GLOBAL BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. BLASTOMYCOSIS MARKET FOR AZOLES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. BLASTOMYCOSIS MARKET FOR AZOLES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. BLASTOMYCOSIS MARKET FOR POLYENES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. BLASTOMYCOSIS MARKET FOR POLYENES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. BLASTOMYCOSIS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. BLASTOMYCOSIS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. GLOBAL BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. BLASTOMYCOSIS MARKET FOR HOSPITAL AND CLINICAL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. BLASTOMYCOSIS MARKET FOR HOSPITAL AND CLINICAL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. BLASTOMYCOSIS MARKET FOR ONLINE PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. BLASTOMYCOSIS MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. BLASTOMYCOSIS MARKET FOR RETAIL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. BLASTOMYCOSIS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. BLASTOMYCOSIS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. NORTH AMERICA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. NORTH AMERICA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. NORTH AMERICA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. NORTH AMERICA BLASTOMYCOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. U.S. BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. U.S. BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. U.S. BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. CANADA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. CANADA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. CANADA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. MEXICO BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. MEXICO BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. MEXICO BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. EUROPE BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. EUROPE BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. EUROPE BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. EUROPE BLASTOMYCOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. GERMANY BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. GERMANY BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. GERMANY BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. FRANCE BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. FRANCE BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. FRANCE BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. UK BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. UK BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. UK BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ITALY BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ITALY BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. ITALY BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. SPAIN BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. SPAIN BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. SPAIN BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. REST OF EUROPE BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. REST OF EUROPE BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. REST OF EUROPE BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. CHINA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. CHINA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. CHINA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. INDIA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. INDIA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. INDIA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. AUSTRALIA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. AUSTRALIA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. AUSTRALIA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. SOUTH KOREA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. SOUTH KOREA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. SOUTH KOREA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. REST OF ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. REST OF ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. REST OF ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. LAMEA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. LAMEA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. LAMEA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. LAMEA BLASTOMYCOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. BRAZIL BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. BRAZIL BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. BRAZIL BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. SOUTH AFRICA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. SOUTH AFRICA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. SOUTH AFRICA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. SAUDI ARABIA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. SAUDI ARABIA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 91. SAUDI ARABIA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 92. REST OF LAMEA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 93. REST OF LAMEA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 94. REST OF LAMEA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 95.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 96.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 97.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 98.PFIZER INC.: NET SALES
  • TABLE 99.PFIZER INC.: KEY STRATERGIES
  • TABLE 100.SANOFI: COMPANY SNAPSHOT
  • TABLE 101.SANOFI: OPERATING SEGMENTS
  • TABLE 102.SANOFI: PRODUCT PORTFOLIO
  • TABLE 103.SANOFI: NET SALES
  • TABLE 104.SANOFI: KEY STRATERGIES
  • TABLE 105.MERCK AND COMPANY: COMPANY SNAPSHOT
  • TABLE 106.MERCK AND COMPANY: OPERATING SEGMENTS
  • TABLE 107.MERCK AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 108.MERCK AND COMPANY: NET SALES
  • TABLE 109.MERCK AND COMPANY: KEY STRATERGIES
  • TABLE 110.GSK: COMPANY SNAPSHOT
  • TABLE 111.GSK: OPERATING SEGMENTS
  • TABLE 112.GSK: PRODUCT PORTFOLIO
  • TABLE 113.GSK: NET SALES
  • TABLE 114.GSK: KEY STRATERGIES
  • TABLE 115.JOHNSON AND JOHNSON MD&D: COMPANY SNAPSHOT
  • TABLE 116.JOHNSON AND JOHNSON MD&D: OPERATING SEGMENTS
  • TABLE 117.JOHNSON AND JOHNSON MD&D: PRODUCT PORTFOLIO
  • TABLE 118.JOHNSON AND JOHNSON MD&D: NET SALES
  • TABLE 119.JOHNSON AND JOHNSON MD&D: KEY STRATERGIES
  • TABLE 120.ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 121.ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 122.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 123.ABBOTT LABORATORIES: NET SALES
  • TABLE 124.ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 125.CELON LABORATORIES LIMITED: COMPANY SNAPSHOT
  • TABLE 126.CELON LABORATORIES LIMITED: OPERATING SEGMENTS
  • TABLE 127.CELON LABORATORIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 128.CELON LABORATORIES LIMITED: NET SALES
  • TABLE 129.CELON LABORATORIES LIMITED: KEY STRATERGIES
  • TABLE 130.SUN PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 131.SUN PHARMACEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 132.SUN PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 133.SUN PHARMACEUTICALS LTD: NET SALES
  • TABLE 134.SUN PHARMACEUTICALS LTD: KEY STRATERGIES
  • TABLE 135.ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
  • TABLE 136.ASTELLAS PHARMA INC.: OPERATING SEGMENTS
  • TABLE 137.ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
  • TABLE 138.ASTELLAS PHARMA INC.: NET SALES
  • TABLE 139.ASTELLAS PHARMA INC.: KEY STRATERGIES
  • TABLE 140.CIPLA LTD: COMPANY SNAPSHOT
  • TABLE 141.CIPLA LTD: OPERATING SEGMENTS
  • TABLE 142.CIPLA LTD: PRODUCT PORTFOLIO
  • TABLE 143.CIPLA LTD: NET SALES
  • TABLE 144.CIPLA LTD: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.BLASTOMYCOSIS MARKET SEGMENTATION
  • FIGURE 2.BLASTOMYCOSIS MARKET,2021-2031
  • FIGURE 3.BLASTOMYCOSIS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.BLASTOMYCOSIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.BLASTOMYCOSIS MARKET,BY FORMULATION,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF TABLETS BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF OINTMENT BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF POWDER BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF LIQUID BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 17.BLASTOMYCOSIS MARKET,BY DRUG TYPE,2021(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF AZOLES BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF POLYENES BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 21.BLASTOMYCOSIS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITAL AND CLINICAL PHARMACY BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACY BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACY BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 25.BLASTOMYCOSIS MARKET BY REGION,2021
  • FIGURE 26.U.S. BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 27.CANADA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 28.MEXICO BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 29.GERMANY BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 30.FRANCE BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 31.UK BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 32.ITALY BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 33.SPAIN BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 34.REST OF EUROPE BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 35.CHINA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 36.INDIA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 37.AUSTRALIA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 38.SOUTH KOREA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 39.REST OF ASIA-PACIFIC BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 40.BRAZIL BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 41.SOUTH AFRICA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 42.SAUDI ARABIA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 43.REST OF LAMEA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 48.COMPETITIVE DASHBOARD
  • FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 50.PFIZER INC..: NET SALES ($MILLION)
  • FIGURE 51.SANOFI.: NET SALES ($MILLION)
  • FIGURE 52.MERCK AND COMPANY.: NET SALES ($MILLION)
  • FIGURE 53.GSK.: NET SALES ($MILLION)
  • FIGURE 54.JOHNSON AND JOHNSON MD&D.: NET SALES ($MILLION)
  • FIGURE 55.ABBOTT LABORATORIES.: NET SALES ($MILLION)
  • FIGURE 56.CELON LABORATORIES LIMITED.: NET SALES ($MILLION)
  • FIGURE 57.SUN PHARMACEUTICALS LTD.: NET SALES ($MILLION)
  • FIGURE 58.ASTELLAS PHARMA INC..: NET SALES ($MILLION)
  • FIGURE 59.CIPLA LTD.: NET SALES ($MILLION)